Table 3.
HPV vaccines in development
| Vaccine Type | Immunogen | Target | Sponsor |
|---|---|---|---|
| Prophylactic Vaccines | |||
| Octavalent vaccine | L1 virus like particle of HPV types 6, 11, 16,18, 31, 45, 52, 58 | Cervical, Anal, Vaginal, Vulvar dysplasia and cancer | Merck |
| V504 (administered with Gardasil) | L1 virus like particles of HPV types 31, 33, 45, 52, 58 | Cervical, Anal, Vaginal, Vulvar dysplasia and cancer | Merck |
| MEDI-517 | Virus like particles of HPV types 16, 18 | Cervical dysplasia and cancer | Glaxo Smith Kline |
| 9-valent vaccine (V503) | L1 virus like particles of HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58 | Cervical, Anal, Vaginal, Vulvar dysplasia and cancer Genital Warts | Merck |
| VGX-3100 | Plasmids targeting E6 and E7 proteins of HPV types 16, 18 | Cervical dysplasia and cancer | Inovio Pharmaceuticals |
| Therapeutic Vaccines | |||
| pNGVL-4a-CRT/E7 (detox) DNA vaccine | E7 DNA of HPV16 | Cervical dysplasia Head and neck cancers | Sidney Kimmel Comprehensive Cancer Center |
| HPV-16 vaccine | 4 HPV 16 E6 proteins | Cervical dysplasia | University of Arkansas |
| TA-HPV | E6 and E7 proteins of HPV 16/18 | Cervical cancer | European Organization for Research and Treatment of Cancer |
| VGX-3100 | Plasmids targeting E6 and E7 proteins of HPV 16/18 | Cervical dysplasia and cancer | Inovio Pharmaceuticals |
| HPV 16 E6 and E7 vaccine | E6 and E7 proteins HPV 16 | Cervical cancer, anal cancer, esophageal cancer, head and neck cancer, penile cancer, vulvar cancer | National Cancer Institute |
| MAGE-A3-HPV 16 | Trojan peptide complexes containing MAGE-A3 and HPV 16 | Head and neck cancer | University of Maryland |
| ADXS11-001 | E7 protein of HPV 16 | Cervical dysplasia and cancer, anal cancer, oropharyngeal cancer | Advaxis |
| Hsp-E7 | Recombinant DNA fusion of heat shock protein 65 and E7 protein of HPV type 16 | Cervical dysplasia | National Cancer Institute, Dana-Farber/Brigham and Women’s Cancer Center |
| Alternating E7 vaccine and dendritic cells presenting E7 | E7 protein of HPV 16 vaccine and dendritic cells presenting E7 protein | Recurrent or persistent cervical cancer | Steward St. Elizabeth’s Medical Center of Boston, National Cancer Institute |
| Gp100: 209–217 and HPV 16 E7: 12–20 peptide | Amino acids 209–217 of glycoprotein 100 melanoma antigen and amino acids 12–20 of E7 protein of HPV 16 | Melanoma | Providence Cancer Center, Earle A. Chiles Research Institute, National Cancer Institute |
Data from Search term “HPV vaccine.” Available at: www.clinicaltrials.gov. Accessed February 28, 2013.